{"title":"Postępowanie terapeutyczne w zespołach mielodysplastycznych niższego ryzyka","authors":"K. Wiśniewski, A. Gołoś, J. Góra-Tybor","doi":"10.5603/HEM.2020.0042","DOIUrl":null,"url":null,"abstract":"Myelodysplastic syndromes (MDS) are acquired clonal disorders of the hematopoietic system caused by a mutation in hematopoietic stem cells. Depending on clinical and laboratory parameters, MDS is divided into two subgroups: low-risk MDS (LR-MDS) and high-risk MDS (HR-MDS), which determines a range of therapeutic options. Recently, some progress in prolongation and quality of life has been observed, mainly due to new therapeutic and supportive methods. The article provides an overview of the current diagnostic and therapeutic approach to lower-risk MDS, as well as manifests the most recent registered therapeutic methods. Additionally, the paper reviews supportive treatment and drugs in clinical trials.","PeriodicalId":38988,"journal":{"name":"Hematologia","volume":"178 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Hematologia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5603/HEM.2020.0042","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0
Abstract
Myelodysplastic syndromes (MDS) are acquired clonal disorders of the hematopoietic system caused by a mutation in hematopoietic stem cells. Depending on clinical and laboratory parameters, MDS is divided into two subgroups: low-risk MDS (LR-MDS) and high-risk MDS (HR-MDS), which determines a range of therapeutic options. Recently, some progress in prolongation and quality of life has been observed, mainly due to new therapeutic and supportive methods. The article provides an overview of the current diagnostic and therapeutic approach to lower-risk MDS, as well as manifests the most recent registered therapeutic methods. Additionally, the paper reviews supportive treatment and drugs in clinical trials.
期刊介绍：
Hematology is the quarterly under auspices of the Institute of Hematology and Transfusion Medicine. The journal is addressed to hematologists, oncologists and also internists. It contains the overview/review articles, case reports, essays, including reports from the scientific and educational conferences as well as test questions on hematology. Journal of the Institute of Hematology and Transfusiology.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
